Lonza Amaxa 4D-Nucleofector system
The Amaxa Nucleofector technology is claimed to be the first efficient non-viral transfection method for primary cells and hard-to-transfect cell lines.
With a new platform, the 4D-Nucleofector system enables nucleofection of cells in several formats, combined with good performance and convenience.
Its features include: transfection of variable cell numbers with same conditions; choice of throughputs from 1 to 16 wells in just 10 s; nucleofection of adherent cells for functional assays at various cellular stages.
The modular system will accommodate upcoming transfection challenges and a current transfection protocol database is available with 690 cells listed, which is continuously updated.
Phone: 1300 657508
Lonza TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium
The products provide researchers and manufacturers with high-performance, scalable and...
Grace Bio-Labs protein microarray tools
Grace Bio-Labs' microarray substrates provide high binding capacity and enable high assay...
Siemens Healthineers 3gAllergy assay
Siemens Healthineers has expanded its 3gAllergy assay menu with nine additional component...
Learn More
I am interested in Lonza Amaxa 4D-Nucleofector system.
Complete the form and a supplier representative will be in touch.
